Aspirin-Fexuprazan Interaction: Clinical PK/PD Model Data

Clinical data from healthy subjects was used to develop a mechanism-based pharmacokinetic/pharmacodynamic model evaluating the interaction between aspirin and the acid blocker fexuprazan. The dataset supports simulations predicting that fexuprazan delays aspirin absorption but does not compromise its antiplatelet efficacy at therapeutic doses. It includes results from single high-dose and simulated low-dose administration regimens.

Use Cases

• Validating mechanism-based PK/PD models for drug-drug interactions involving gastric pH changes.
• Simulating the pharmacokinetic impact of acid suppressants on aspirin absorption.
• Assessing the pharmacodynamic dissociation between absorption delay and maintained antiplatelet effect.
• Informing clinical guidance on co-administering aspirin with potassium-competitive acid blockers.

Strengths

• Dataset is underpinned by a specific, described mechanism-based PK/PD modeling approach.
• Contains clinical data from healthy subjects for both single high-dose (500mg aspirin, 80mg fexuprazan) and simulated therapeutic low-dose regimens.
• Released under a permissive CC-BY-4.0 license, facilitating reuse and redistribution.

Limitations

• Column names and a precise row count are not provided, limiting understanding of the data structure.
• The dataset's temporal coverage and the institution of the author are not specified.
• The most recent update date (2026-03-24) is a future date, indicating a potential metadata error.

Provenance

Source

Eunsuk Yang

Collection Method

Clinical data from healthy subjects administered aspirin alone or with fexuprazan, used for PK/PD model development and simulation.

Time Range

null

Freshness

2026-03 24 03:46:31

Geography

null